Emergent BioSolutions, Inc. (EBS)
11.41
+0.31
(+2.79%)
USD |
NYSE |
Jan 21, 12:52
Emergent BioSolutions Research and Development Expense (Annual): 64.90M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp. | 1.615B |
| Eli Lilly & Co. | 10.99B |
| Penumbra, Inc. | 94.78M |
| Disc Medicine, Inc. | 96.52M |
| Black Diamond Therapeutics, Inc. | 50.97M |